Disclosure: The author has a short position in one or more of the shares mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
Those who listened to Australian fund manager John Hempton speak at the Gold and Bears show last November will know that attention to detail is very much his thing. They will have heard him mutter that he believed US Pharmaceutical giant Valeant, based in Canada, to be worthless. This has been a bold call with ranks of hedge fund royalty (the most prominent being the unbelievably arrogant Bill Ackman) lined up against him.